Sanford C. Bernstein set a €115.00 ($136.90) price target on Merck KGaA (FRA:MRK) in a report published on Wednesday. The brokerage currently has a buy rating on the healthcare company’s stock.
Several other research firms also recently issued reports on MRK. JPMorgan Chase & Co. set a €95.00 ($113.10) price objective on Merck KGaA and gave the stock a neutral rating in a report on Wednesday, January 10th. UBS Group set a €120.00 ($142.86) price objective on Merck KGaA and gave the stock a buy rating in a report on Monday, January 8th. Kepler Capital Markets set a €115.00 ($136.90) price objective on Merck KGaA and gave the stock a buy rating in a report on Monday, November 6th. Warburg Research set a €115.00 ($136.90) price objective on Merck KGaA and gave the stock a buy rating in a report on Thursday, November 9th. Finally, Independent Research set a €103.00 ($122.62) price objective on Merck KGaA and gave the stock a neutral rating in a report on Thursday, November 9th. Twelve equities research analysts have rated the stock with a hold rating and ten have issued a buy rating to the company’s stock. Merck KGaA currently has a consensus rating of Hold and an average target price of €107.57 ($128.06).
Shares of Merck KGaA (FRA MRK) opened at €89.66 ($106.74) on Wednesday. Merck KGaA has a 1-year low of €87.33 ($103.96) and a 1-year high of €115.00 ($136.90). The firm has a market cap of $11,650.00 and a PE ratio of 21.00.
COPYRIGHT VIOLATION WARNING: “Sanford C. Bernstein Analysts Give Merck KGaA (MRK) a €115.00 Price Target” was first posted by Dispatch Tribunal and is the property of of Dispatch Tribunal. If you are accessing this piece of content on another domain, it was stolen and reposted in violation of United States and international trademark & copyright law. The legal version of this piece of content can be read at https://www.dispatchtribunal.com/2018/01/20/sanford-c-bernstein-analysts-give-merck-kgaa-mrk-a-115-00-price-target.html.
Merck KGaA Company Profile
MERCK Kommanditgesellschaft auf Aktien provides products in the healthcare, life science, and performance materials sectors worldwide. The company offers prescription medicines to treat colorectal cancer, head and neck tumors, multiple sclerosis, infertility, growth hormone disorders, cardiovascular disorders, diabetes, and thyroid disorders; diagnostics and prescription drugs for allergen immunotherapy; and biosimilars for oncology and inflammatory disorders.
Receive News & Ratings for Merck KGaA Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Merck KGaA and related companies with MarketBeat.com's FREE daily email newsletter.